Related Experiment Video
Updated: Aug 17, 2026

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients
Published on: February 11, 2017
Recent advances in the treatment of cystic fibrosis
1Department of Pediatrics, University of Cincinnati College of Medicine, Ohio.
Abstract:
Cystic fibrosis is a serious, common genetic condition that causes recurrent pulmonary infections, malabsorption, and increased sweat electrolytes. Despite significant improvements in clinical treatment, individuals continue to die from progressive, obstructive pulmonary disease as children and young adults. This article reviews the current status of our understanding of cystic fibrosis: the basic defect, animal models, current therapy, and new approaches to the pulmonary disease.
Related Concept Videos
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Drugs for Treatment of Constipation-Predominant IBS
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Chronic Pancreatitis II: Collaborative Care
Assessment:
Pharmacogenomics: Identification of New Drug Targets
Cardiopulmonary Resuscitation V: Advanced Airway Management Techniques

